XENE

In May 2026, Xenon held its Q1 2026 earnings conference call and presented at the RBC Capital Markets Global Healthcare Conference and the Bank of America Global Healthcare Conference. In June 2026, the company presented at the Jefferies Global Healthcare Conference. The Q2 2026 earnings conference call in August 2026 reported a quarterly loss of ($1.11) per share, beating estimates. In September 2026, Xenon presented at the Wells Fargo Healthcare Conference and the TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. A significant event on September 17, 2026, was the submission of an NDA for azetukalner in focal onset seizures, coupled with a voluntary pause in new patient enrollment for its Phase 3 psychiatry trials due to neuropsychiatric adverse events, which led to a substantial stock price decrease. Following this, the CEO and CFO made insider purchases totaling approximately $1.68 million on September 30, 2026, near the stock's 52-week low, and the company reported inducement grants on October 2, 2026. Analyst downgrades, including a 'Strong Sell' rating from Wall Street Zen, also occurred after the psychiatry trial pause.